Immune cells for viral infections after transplant
Part of Infections clinical trials.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell or organ transplant, or have a primary immune deficiency, or are on immunosuppressive therapy.
- You have an active infection with adenovirus, CMV, or EBV that hasn't gotten better with standard treatments.
- You are between 1 month and 65 years old.
- You can lower steroid doses to less than 1 mg/kg/day before treatment (if needed).
- You do not have severe graft-versus-host disease (GVHD) or an uncontrolled cancer relapse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests whether giving special immune cells (called cytotoxic T lymphocytes) can fight viruses like CMV, adenovirus, EBV, or BK virus that are not responding to usual treatments. It is for people aged 0 to 29 with weakened immune systems due to inherited conditions or previous transplants.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
This trial is testing whether giving special immune cells from a family donor (called CTLs) along with regular antiviral medicine is better than regular medicine alone for people who have a stubborn adenovirus or cytomegalovirus infection after a stem cell transplant.
Hear when a new Adenovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.